BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Eli Lilly and Kumquat Seek Enhanced Tumor-Specific Immune Response in $2B+ Deal

  The two companies announced their exclusive collaboration that will harness Kumquat’s small molecule immuno-oncology platform’s capabilities to discover novel clinical candidates.

  July 29, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Three Biopharma Companies Made Public Debut on Nasdaq Exchange

  Nuvalent, Rallybio and Icosavax all began selling on the Nasdaq Exchange today.

  July 29, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Future of AstraZeneca’s Vaccine Business is Murky, But Seeks to Move Ahead with FDA Filing

  AstraZeneca said in an earnings announcement on Thursday it will seek authorization for its COVID-19 vaccine in the U.S. sometime in the second half of this year.

  July 29, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  FDA

  New Day For Diabetes Patients As FDA Approves First-Ever Interchangeable Biosimilar

  Semglee was approved under the FDA’s 351(k) pathway, a biologics license application process. It ensures that the bio similarity is based on animal studies, clinical trials, and analytical studies.

  July 29, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  BioForest

  Research Roundup: Immune Memory Against COVID-19 and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  July 29, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Policy

  Kaiser Sues Merck, Generic Drug Firm Over Millions in Losses Due to Alleged “Pay-for-Delay” Scheme

  Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a “pay-for-delay” scheme that cost the former millions of dollars.

  July 29, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Vaxart Sees Boosting Immunity with Oral Norovirus Vaccine Candidate, Hope for COVID-19

  Clinical-stage biotech company Vaxart announced Thursday that a second dose of its oral norovirus vaccine boosted immunity in clinical trial participants who had previously received the vaccine more than a year prior.

  July 29, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Business

  bluebird bio and National Resilience Ink Cell Therapy Strategic Alliance

  bluebird bio and National Resilience signed a strategic alliance around cell therapies. As part of the deal, Resilience is buying bluebird’s manufacturing facility in Research Triangle Park, keeping more than 100 staffers.

  July 29, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  COVID News: EUA Expanded for Baricitinib, Emergent Starts to Manufacture J&J Vaccine Again and More

  As COVID-19 infections continue to increase in the U.S., the FDA has expanded the EUA for Eli Lilly’s monoclonal antibody to include treatment with or without remdesivir.

  July 29, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Career Advice

  Counterproductive Career Advice That You Should Ignore

  Getting job-hunting and career advice is hard, especially when you get it from those who have worked for decades. Some advice is still helpful today, like making a good impression, but others are considered counter-productive.

  July 29, 2021

   · 

  3 min read

   · 

  Lorenzo Soliman